06/24/2020 12:00 AM EDT
Source: National Emerging Special Pathogens Training and Education Center (NETEC). Published: 6/24/2020. This 56-minute webinar features speakers who discuss workforce resilience during the COVID-19 pandemic, challenges for healthcare workers in a pandemic, lessons learned from Nebraska Medicine, and reconnecting during the "new normal." (Video or Multimedia)
06/23/2020 12:00 AM EDT
Source: Harvard University. Published: 6/23/2020. This one-hour, three-minute webinar brings together digital health experts from across sectors to address some of the most critical questions surrounding the use of chatbots as a public health tool. Panelists discuss why chatbots can play a critical role in the COVID-19 response, especially in low resource settings; explore the shortcomings to using these tools and ways to overcome them; and share the next steps to maximizing the potential of chatbots and mitigating harm. (Video or Multimedia)
06/23/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/23/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the GenePro SARS-CoV-2 Test. The GenePro SARS-CoV-2 Test is authorized for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
06/23/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/23/2020. This seven-page letter details the Emergency Use Authorization (EUA) for the FRL SARS CoV-2 Test for qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab, oropharyngeal swab, anterior nasal swab, mid-turbinate nasal swab, nasopharyngeal wash/aspirate, nasal aspirate, and bronchoalveolar lavage specimens from individuals suspected of COVID-19 by their healthcare provider. (PDF)
06/23/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/23/2020. This seven-page letter details the Emergency Use Authorization (EUA) for the HealthQuest Esoterics TaqPath SARS-CoV-2 Assay for qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab, oropharyngeal swab, anterior nasal swab, mid-turbinate nasal swab, nasopharyngeal wash/aspirate, nasal aspirate, and bronchoalveolar lavage specimens from individuals suspected of COVID-19 by their healthcare provider. (PDF)
06/23/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/23/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Babson Diagnostics aC19G1 test. The Babson Diagnostics aC19G1 test is authorized for the detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (potassium EDTA, lithium heparin). (PDF)
06/23/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 6/23/2020. This guidance is meant to assist Ministries of Health and their point-of-entry (POE) partners in determining whether and how to conduct traveler screening at POE for coronavirus (COVID-19). The objective of screening is to reduce the international spread of communicable disease by detecting departing travelers who are sick or who have been exposed to the disease and preventing them from leaving the country they are in (exit screening) or by detecting them upon arrival and directing them to appropriate care and follow-up, as needed (entry screening). (Text)
06/22/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/22/2020. This seven-page letter, updated on June 22, 2020, authorizes the emergency use of the COVID-19 Airway Management Isolation Chamber. This device is authorized for use by healthcare providers (HCP) as an extra layer of barrier protection in addition to personal protective equipment (PPE) to prevent HCP exposure to pathogenic biological airborne particulates during transport of patients, at the time of definitive airway management, or when performing medical procedures on such patients during the COVID-19 pandemic. (PDF)
06/17/2020 12:00 AM EDT
Source: Johns Hopkins University, Bloomberg School of Public Health. Published: 6/17/2020. When a COVID-19 vaccine becomes available, it will effectively stop disease transmission only if it reaches the people who need it. In this one-hour, two-minute webinar, experts on epidemiology, policy, and advocacy at the International Vaccine Access Center discuss consideration of decision-making processes and opportunities for innovation to optimize delivery and impact. (Video or Multimedia)
06/01/2020 12:00 AM EDT
Source: United Nations Population Fund (UNFPA). Published: 6/2020. The United Nations Population Fund for West and Central Africa Regional Office commissioned this 32-page review of responses to major epidemics. The study examined major epidemics since 2003, including SARS-CoV, HIV/AIDS, Ebola, Zika, and MERS-CoV. (PDF)
05/06/2020 12:00 AM EDT
Source: U.S. Senate, Committee on Homeland Security and Governmental Affairs. Published: 5/6/2020. This three-hour, 15-minute Congressional discussion focuses on the science, data, and information that are needed for a safety reopening of the U.S. economy during the COVID-19 pandemic, and how that information should drive public health policy. (Video or Multimedia)
05/01/2020 12:00 AM EDT
Source: U.S. Department of Homeland Security (DHS). Published: 5/1/2020. Due to the global shortage of respirators, medical masks, and similar personal protective equipment, conservation and reuse of this equipment is critical for COVID-19 efforts. The purpose of this 16-page document is to provide an overview of available data with regard to different types of respiratory protection, medical masks, and homemade masks, and which disinfection methods are recommended. (PDF)
No hay comentarios:
Publicar un comentario